FilingReader Intelligence
Joinus Pharma gains US FDA approval for nicardipine injection
August 21, 2025 at 08:29 AM UTC•By FilingReader AI
Nanjing King-Friend Biochemical Pharmaceutical received US FDA approval for its nicardipine hydrochloride injection on August 20, 2025. The drug treats short-term hypertension when oral administration isn't feasible.
The company invested approximately RMB 1.84 billion in research and development for this project.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:603707•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Nanjing King-Friend Biochemical Pharmaceutical publishes news
Free account required • Unsubscribe anytime